A Phase 1 study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in patients with advanced solid tumors
Recruiting Phase 1 NCT07660055
Study Description
A study testing a new radioactive treatment ([177Lu]Lu-DWJ155) and a matched imaging agent ([68Ga]Ga-DWJ155) in patients with certain advanced cancers, including breast, lung, stomach, and bladder cancer, to find the right dose and assess safety and early signs of effectiveness
Study Details
- Registry ID:
- NCT07660055
- Conditions:
- Breast Cancer, Non-small Cell Lung Cancer (NSCLC), Gastric/Gastroesophageal Junction (GEJ) Cancer, Bladder Cancer
- Phase:
- Phase 1
- Target Enrollment:
- 156 participants
- Start Date:
- Age Range:
- 18–999 years
- Healthy Volunteers:
- No
Study Locations (4 sites)
-
Novartis Investigative Site
Montreal, Quebec, Canada -
Nebraska Cancer Specialists
Omaha, Nebraska, United States -
Novartis Investigative Site
Kashiwa, Chiba, Japan -
Novartis Investigative Site
Darlinghurst, New South Wales, Australia
Interested in Participating?
Check your eligibility and learn more about this study on TrialScreen.